There is a lot to unpack about this week’s FDA Advisory Panel hearing on Gilead’s new cash cow option for pre-exposure prophylaxis (PrEP), Descovy. I want to point you to the coverage that best suits you, including terrific reporting from an Australian radio show (!)...














